Ocular Therapeutix Gears Up for Major Conferences This September
Ocular Therapeutix Announces Major Conference Participation
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a pivotal player in the biopharmaceutical landscape, is set to engage with investors and the scientific community in an array of key conferences this September. Their commitment to transforming the retina experience reflects the significant strides they are making in ocular health.
Engagement in Investor Conferences
Morgan Stanley Annual Global Healthcare Conference
The first major event is the Morgan Stanley 23rd Annual Global Healthcare Conference, scheduled for September 8, 2025, at 2:35 PM ET. Pravin U. Dugel, MD, the Executive Chairman, President, and CEO of Ocular Therapeutix, will actively participate in a fireside chat, discussing the company's vision and developments.
Baird Global Healthcare Conference
Following that, the Baird 2025 Global Healthcare Conference will feature Ocular’s leadership on September 9 at 12:50 PM ET. Dr. Dugel will continue to guide discussions about the company's groundbreaking approaches to retinal diseases.
Both events will offer live webcasts and are vital opportunities for stakeholders to gain insight into Ocular’s ongoing projects and overall strategy.
Scientific Conferences Highlighting Innovations
Participation in EURETINA Conferences
Ocular Therapeutix will also participate in a host of scientific forums, beginning with the EURETINA Innovation Spotlight on September 3, 2025. During this event, Peter K. Kaiser, MD, Chief Development Officer, will present on the company’s innovative products aimed at redefining the retina experience.
Ophthalmology Futures Forums
On the same day, Ocular will feature prominently in the Ophthalmology Futures Forums, discussing critical topics like diabetic retinopathy and innovations surrounding Tyrosine Kinase Inhibitors (TKIs). These forums promise multidimensional insights into the evolving landscape of ocular therapies.
Ongoing Research and Development
Phase 3 Clinical Trials
Central to Ocular’s mission is AXPAXLI™ (OTX-TKI), their investigational product currently in Phase 3 clinical trials. This axitinib intravitreal hydrogel exemplifies Ocular's pioneering efforts in treating wet age-related macular degeneration.
Commercial Product DEXTENZA®
Moreover, Ocular's commercial product DEXTENZA® continues to establish itself as a vital treatment for ocular inflammation and pain post-surgery, as well as for allergic conjunctivitis. This FDA-approved corticosteroid underscores the efficacy of Ocular’s proprietary ELUTYX™ technology.
Additionally, OTX-TIC, another investigational solution, is being explored for its potential in managing open-angle glaucoma through innovative hydrogel formulations.
Branding and Community Engagement
The company is committed to community awareness and invites everyone to explore their updated corporate branding online. Ocular Therapeutix emphasizes the importance of engaging with patients and the wider community, illustrating their dedication to ocular health.
Their presence at these conferences not only showcases their advancements but also reinforces their place as a leader in the biopharmaceutical sector, dedicated to redefining treatment modalities.
Frequently Asked Questions
What conferences will Ocular Therapeutix participate in September?
Ocular Therapeutix is set to participate in various investor and scientific conferences, including the Morgan Stanley and Baird Global Healthcare Conferences, and EURETINA events.
Who will represent Ocular Therapeutix at these events?
Pravin U. Dugel, MD, will represent the company at the investor conferences, while other experts like Peter K. Kaiser, MD, will handle presentations at scientific gatherings.
What is AXPAXLI™?
AXPAXLI™ (also known as OTX-TKI) is an investigational drug designed to treat wet age-related macular degeneration and is currently undergoing Phase 3 clinical trials.
What is DEXTENZA® used for?
DEXTENZA® is an FDA-approved corticosteroid that treats ocular inflammation and pain following surgery, as well as itching related to allergic conjunctivitis.
How can stakeholders stay informed about Ocular Therapeutix?
Stakeholders can follow Ocular Therapeutix on their website and social media platforms to receive updates on upcoming events, company news, and product information.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.